Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 7/20 | 1.00 |
| ▸ | PGK1 | P00558 | 1/20 | 0.77 |
| ▸ | PGK2 | P07205 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6758941 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL27578766 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL14853634 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL5879766 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL18464461 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL14928752 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL21276447 | 0.92 | ADORA3 (0.86) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL22224967 | 0.91 | ADORA3 (0.84) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL23760829 | 0.90 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL20724628 | 0.90 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501512-B2 | Modified polynucleotides | MODERNATX, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| EP-3520820-A1 | IN VIVO PRODUCTION OF PROTEINS | Moderna Therapeutics, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9878056-B2 | Modified polynucleotides for the production of cosmetic proteins and peptides | MODERNATX, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9790531-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782462-B2 | Modified polynucleotides for the production of proteins associated with human disease | MODERNATX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170130255-A1 | ENZYMES AND POLYMERASES FOR THE SYNTHESIS OF RNA | MODERNATX, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-7381714-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-20060276428-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276428-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA1 1/4885PGK1 1806/4885 |
| US-10501512-B2 | Modified polynucleotides | POLRMT, POLN, MSH2 | ADORA3 1838/4885ADORA1 2389/4885PGK1 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.